先端分野の市場情報を提供する株式会社グローバルインフォメーション（神奈川県川崎市、代表取締役 社長：小野 悟）は、2011年1月31～2月2日 米国、サンディエゴにて開催されます、Cambridge Healthtech Institute主催 国際会議・展示会「Biomarker Assay Development ...

CHIの第4回年次会議Biomarker Assay Developmentでは、前臨床開発と臨床開発を網羅する“目的に合わせた”手法の開発、および診断薬開発について取り扱います。この会議では、ゲノミクス、プロテオミクス分析のための新規アッセイプラットフォームの概要のほか ...

Creating a clear and well-defined bioanalytical methodology to quantify humoral and cellular immune responses is critical for ...

In this roundtable webinar, discover how scientists improve tumor-informed minimal residual disease (MRD) testing for ...

Assays are investigative procedures that qualitatively assess a compound or examine a compound’s effects on identified molecular, cellular, or biochemical targets. The first steps in drug development ...

Molecular diagnostic assay development and design is no simple task, and several factors affect the performance and usability of a test. Diagnostic companies can enhance assay stability and ...

FREMONT, Calif., Feb. 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the ...

Market Growth Driven by Rising Chronic Disease Prevalence, Increasing Geriatric Population, High Burden of Infectious Diseases, and Growing Focus on Point-of-Care IVD Assays REDDING, Calif., June 30, ...

The latest advances in genome sequencing indicate proteases occur naturally in all organisms and account for about 2% of the human genome and 1–5% of genomes of infectious organisms. The human genome ...